Search





Search





Markets
/
Stocks
/
gtbp
/

GT Biopharma Inc

GTBP

Add to Watchlist

0.290USD

-0.018-5.69%

Close 07-31 16:00（ET）Quotes delayed by 15 min

1.76MMarket Cap

LossP/E TTM

GT Biopharma Inc

0.290

-0.018-5.69%

Financial Summary Income Statement Balance Sheet Cash Flow Statement

Overview

Financials

Discussions

Analysis

Company

Financial Summary Income Statement Balance Sheet Cash Flow Statement

GTBP Financials

See GT Biopharma Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.

GT Biopharma Inc Earnings Date

Latest Release

May 15, 2026

EPS / Forecast

-0.11/-0.08

Revenue / Forecast

0.00/0.00

See Upcoming Earnings >>

Period

FY2025 Earnings

Revenue(YoY)

EPS(YoY)

-6.25

9.93%

Analyst Rating

BUY

2026/07/31

Quarterly

Quarterly+Annual

Quarterly

Annual

YOY

Hide blank rows

FY2026Q1

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021Q4

FY2021Q3

FY2021Q2

Financial Indicators

EPS

66.38%-0.11

-33.16%-2.23

45.84%-0.83

74.73%-0.55

79.84%-0.33

22.02%-1.67

13.60%-1.53

-45.67%-2.17

-841.64%-1.64

58.65%-2.14

---1.77

---1.49

---0.17

---5.19

----

Revenue

--0.00

----

--0.00

----

--0.00

Net Profit

-334.15%-3.37M

-665.48%-28.90M

4.49%-3.26M

59.08%-1.52M

65.75%-776.00K

-27.45%-3.77M

-41.18%-3.41M

-86.24%-3.71M

-898.24%-2.27M

46.96%-2.96M

64.89%-2.42M

33.13%-1.99M

95.83%-227.00K

69.02%-5.58M

-26.19%-6.88M

38.72%-2.98M

81.67%-5.44M

-20.69%-18.02M

-89.60%-5.45M

72.10%-4.86M

Debt to assets ratio

----

--0.00%

----

--0.00%

----

Income Statement

Revenue

--0.00

----

--0.00

----

--0.00

Operating profit

-47.41%-2.85M

-48.68%-5.59M

6.16%-3.38M

61.26%-1.51M

37.50%-1.93M

-18.78%-3.76M

-15.44%-3.60M

-7.87%-3.91M

15.66%-3.09M

45.17%-3.17M

55.55%-3.12M

-20.14%-3.62M

32.65%-3.67M

68.21%-5.78M

-17.95%-7.02M

31.20%-3.01M

81.24%-5.44M

-729.67%-18.18M

-206.12%-5.95M

-181.19%-4.38M

Net Profit

-334.15%-3.37M

-665.48%-28.90M

4.49%-3.26M

59.08%-1.52M

65.75%-776.00K

-27.45%-3.77M

-41.18%-3.41M

-86.24%-3.71M

-898.24%-2.27M

46.96%-2.96M

64.89%-2.42M

33.13%-1.99M

95.83%-227.00K

69.02%-5.58M

-26.19%-6.88M

38.72%-2.98M

81.67%-5.44M

-20.69%-18.02M

-89.60%-5.45M

72.10%-4.86M

Balance Sheet

Current assets

276.07%10.00M

91.54%8.11M

-36.07%4.32M

-23.13%7.12M

-73.11%2.66M

-69.89%4.23M

-57.89%6.76M

-48.58%9.27M

-50.42%9.88M

-15.13%14.06M

-23.09%16.05M

-24.75%18.02M

-26.68%19.94M

-48.52%16.56M

-41.70%20.87M

-39.48%23.95M

-1.63%27.19M

468.26%32.17M

4197.48%35.80M

3974.87%39.57M

Total current liabilities

-33.59%2.42M

-60.71%2.32M

-71.66%1.32M

-38.63%2.31M

-20.91%3.64M

-11.02%5.90M

-8.41%4.66M

-22.38%3.76M

12.86%4.60M

34.33%6.63M

1.29%5.09M

-43.75%4.84M

-57.11%4.08M

-51.87%4.94M

28.12%5.03M

162.82%8.61M

162.08%9.50M

-70.77%10.26M

-87.22%3.92M

-88.53%3.28M

Total assets

276.07%10.00M

91.54%8.11M

-36.07%4.32M

-23.13%7.12M

-73.18%2.66M

-70.00%4.23M

-58.14%6.76M

-48.93%9.27M

-50.65%9.91M

-15.70%14.11M

-23.36%16.15M

-24.93%18.14M

-26.80%20.09M

-47.97%16.74M

-41.14%21.07M

-38.91%24.17M

-0.74%27.44M

468.26%32.17M

3803.82%35.80M

3622.20%39.57M

Total liabilities

-33.59%2.42M

-60.71%2.32M

-71.66%1.32M

-38.63%2.31M

-20.91%3.64M

-11.02%5.90M

-24.11%4.66M

-41.09%3.76M

-34.59%4.60M

32.61%6.63M

20.05%6.14M

-26.91%6.38M

-27.12%7.03M

-51.24%5.00M

30.47%5.12M

166.48%8.73M

166.13%9.65M

-70.77%10.26M

-87.22%3.92M

-88.53%3.28M

Total equity

873.47%7.58M

446.53%5.79M

43.06%3.00M

-12.55%4.82M

-118.45%-980.00K

-122.34%-1.67M

-79.04%2.10M

-53.18%5.51M

-59.30%5.31M

-36.29%7.48M

-37.29%10.01M

-23.81%11.76M

-26.62%13.05M

-46.44%11.73M

-49.95%15.95M

-57.46%15.44M

-25.93%17.79M

174.44%21.91M

207.05%31.88M

231.97%36.29M

Cash Flow Statement

Net operating income

-12.08%-2.47M

-62.93%-4.02M

-34.34%-3.68M

14.76%-3.01M

47.11%-2.20M

-20.57%-2.47M

-39.36%-2.74M

-82.74%-3.54M

-43.26%-4.16M

52.37%-2.05M

32.69%-1.96M

30.55%-1.94M

44.28%-2.91M

-16.01%-4.30M

25.73%-2.92M

35.03%-2.79M

-41.56%-5.21M

-92.27%-3.71M

-130.98%-3.93M

-25.71%-4.29M

Net investment

----

-100.00%0.00

-99.79%1.00K

-100.05%-1.00K

195.78%7.86M

172.03%5.03M

-93.63%478.00K

7280.00%1.84M

145.79%2.66M

-297.82%-6.99M

150.95%7.51M

100.10%25.00K

--1.08M

--3.53M

--2.99M

---26.03M

----

Net financing

643.51%4.58M

--8.30M

--977.00K

97.48%5.88M

--616.00K

--0.00

--2.98M

-100.00%0.00

100.00%0.00

--0.00

100.00%0.00

--6.27M

---1.00K

-100.00%0.00

-101.37%-223.00K

-100.00%0.00

-88.58%137.00K

281.44%16.24M

FAQs

What are the current assets of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its current assets were 8.11M, with a year-on-year change of 91.54.

What are the total assets of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its total assets of GT Biopharma Inc were 8.11M, with a year-on-year change of 91.54.

What are the total liabilities of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its total liabilities of GT Biopharma Inc were 2.32M, with a year-on-year change of -60.71.

What is the total equity of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its total equity of GT Biopharma Inc was 5.79M, with a year-on-year change of 446.53.

What is the net operating income of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its net operating income of GT Biopharma Inc was -12.42M, with a year-on-year change of 13.52.

What is the net financing of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its net financing of GT Biopharma Inc was 15.78M, with a year-on-year change of 430.07.

What is the Earnings Per Share (EPS) of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -6.25, with a year-on-year change of 9.93.

What is the net income of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its net income was -34.45M, with a year-on-year change of -161.73.

What is the Return on Equity (ROE) of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its Return on Equity (ROE) was -1674.31, with a year-on-year change of -269.16.

What is the Return on Assets (ROA) of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its Return on Assets (ROA) was -459.62, with a year-on-year change of -220.24.

What is the operating profit of GT Biopharma Inc?



According to GT Biopharma Inc's FY2025 earnings report, its operating profit was -12.42M, with a year-on-year change of 13.52.